Selective self-induced stimulus amplification prodrug platform for inhibiting multidrug resistance and lung...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Research

Background:

• Tumor heterogeneity and multidrug resistance (MDR) limit the efficacy of current cancer therapies.
• Stimuli-responsive nanocarriers face challenges in clinical application due to tumor heterogeneity.

Purpose of the Study:

• To develop a tumor redox heterogeneity-responsive prodrug with self-induced reactive oxygen species (ROS) amplification.
• To enhance drug release, overcome MDR, and prevent lung metastasis.

Main Methods:

• Prodrug self-assembly into polymer micelles (PMs) with high drug loading (~30%).
• Evaluation of PMs' physiological stability, circulation time, and tumor distribution.
• Investigation of ROS signal amplification for triggered drug release.
• Assessment of ROS-induced apoptosis and inhibition of drug resistance mechanisms (Bcl-2 family, mitochondrial potential, ATP levels).

Main Results:

• PMs demonstrated high drug loading, stability, and enhanced tumor accumulation.
• Prodrug PMs effectively amplified tumor-specific ROS, enabling rapid drug release.
• Elevated ROS induced apoptosis and reversed both inherent and acquired drug resistance.
• Significant inhibition of tumor growth in S180 and MCF-7/ADR models and prevention of lung metastasis in 4T1 models.

Conclusions:

• The developed prodrug PMs offer a promising strategy for overcoming tumor heterogeneity and MDR.
• This approach provides a novel stimuli-responsive nanocarrier system for efficient cancer therapy.
• The self-induced ROS amplification mechanism is key to enhanced therapeutic outcomes.